![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P Popik, RT Layer, LH Fossom, M Benveniste, B Geter-Douglass, JM Witkin and P Skolnick
Laboratory of Neuroscience, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Both anecdotal reports in humans and preclinical studies indicate that ibogaine interrupts addiction to a variety of abused substances including alcohol, opiates, nicotine and stimulants. Based on the similarity of these therapeutic claims to recent preclinical studies demonstrating that N-methyl-D-aspartate (NMDA) antagonists attenuate addiction-related phenomena, we examined the NMDA antagonist properties of ibogaine. Pharmacologically relevant concentrations of ibogaine produce a voltage-dependent block of NMDA receptors in hippocampal cultures (Ki, 2.3 microM at -60 mV). Consistent with this observation, ibogaine competitively inhibits [3H]1-[1-(2-thienyl)- cyclohexyl]piperidine binding to rat forebrain homogenates (Ki, 1.5 microM) and blocks glutamate-induced cell death in neuronal cultures (IC50, 4.5 microM). Moreover, at doses previously reported to interfere with drug-seeking behaviors, ibogaine substitutes as a discriminative stimulus (ED50, 64.9 mg/kg) in mice trained to discriminate the prototypic voltage-dependent NMDA antagonist, dizocilpine (0.17 mg/kg), from saline. Consistent with previous reports, ibogaine reduced naloxone-precipitated jumping in morphine-dependent mice (ED50, 72 mg/kg). Although pretreatment with glycine did not affect naloxone- precipitated jumping in morphine-dependent mice, it abolished the ability of ibogaine to block naloxone-precipitated jumping. Taken together, these findings link the NMDA antagonist actions of ibogaine to a putative "antiaddictive" property of this alkaloid, its ability to reduce the expression of morphine dependence.
This article has been cited by other articles:
|
|
 |
|
  R Maciulaitis, V Kontrimaviciute, F. Bressolle, and V Briedis Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review Human and Experimental Toxicology, March 1, 2008; 27(3): 181 - 194. [Abstract] [PDF]
|
|
|
|
 |
|
 J. C. Delorenzi, L. Freire-de-Lima, C. R. Gattass, D. de Andrade Costa, L. He, M. E. Kuehne, and E. M. B. Saraiva In Vitro Activities of Iboga Alkaloid Congeners Coronaridine and 18-Methoxycoronaridine against Leishmania amazonensis Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2111 - 2115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Popik and W. Danysz Inhibition of Reinforcing Effects of Morphine and Motivational Aspects of Naloxone-Precipitated Opioid Withdrawal by N-Methyl-D-aspartate Receptor Antagonist, Memantine J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 854 - 865. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Badio, W. L. Padgett, and J. W. Daly Ibogaine: A Potent Noncompetitive Blocker of Ganglionic/Neuronal Nicotinic Receptors Mol. Pharmacol., January 1, 1997; 51(1): 1 - 5. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
